<DOC>
	<DOCNO>NCT00788424</DOCNO>
	<brief_summary>This protocol relate phase II randomize double blind , placebo control study AS101 topical application treatment mild moderate Psoriasis .</brief_summary>
	<brief_title>Topical Application AS101 Treatment Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<criteria>1 . Patient diagnose mild moderate stable plaque type psoriasis ( le 10 % body skin surface ) . 2 . Patient must 1870 year age . 3 . General health must adequate allow compliance requirement protocol . 4 . Patient his/her legal guardian must sign informed consent form prior study participation . 5 . Patient must able willing comply protocol requirement . 1 . Patients mentally disabled otherwise unable provide fully inform consent . 2 . Pregnant breastfeeding female . 3 . Patients evidence infection target zone . 4 . Patients known sensitivity drug component . 5 . Patients treat systemic anti psoriatic medication within one month prior initial treatment AS101 , topical anti psoriatic preparation within two week prior initial treatment AS101 . 6 . Patient psoriatic arthritis . 7 . Patients take immunosuppressive drug . 8 . Immunocompromised patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>AS101 Psoriasis</keyword>
</DOC>